MEDICUS PHARMA LTD (MDCX) Stock Overview
USA - NASDAQ:MDCX - CA58471K2020 - Common Stock
MDCX Key Statistics, Chart & Performance
The current stock price of MDCX is 2.5075 USD. In the past month the price increased by 2.66%.
MDCX Latest News, Press Relases and Analysis
MDCX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.56 | 403.29B | ||
| AMGN | AMGEN INC | 13.31 | 156.33B | ||
| GILD | GILEAD SCIENCES INC | 15.54 | 149.26B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.91 | 108.19B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.79 | 61.87B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 61.83B | ||
| ARGX | ARGENX SE - ADR | 89.46 | 50.73B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.16 | 35.09B | ||
| INSM | INSMED INC | N/A | 34.04B | ||
| NTRA | NATERA INC | N/A | 26.16B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.34B | ||
| BIIB | BIOGEN INC | 9.37 | 21.98B |
Related stock screener links
About MDCX
Company Profile
Medicus Pharma Ltd. is a biotech life sciences company, which focuses on accelerating the clinical development programs of novel and disruptive therapeutic assets. The company is headquartered in Conshohocken, Pennsylvania. The company went IPO on 2023-10-11. SkinJect Inc., a wholly owned subsidiary of the Company, is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver a chemotherapeutic agent to eradicate tumors cells. The company is conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in the United States and Europe. The company has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in the UAE. Its subsidiary, Antev Limited, is a late clinical stage biotech company, developing Teverelix, a GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse episodes due to enlarged prostate.
Company Info
MEDICUS PHARMA LTD
300 Conshohocken State Rd., Suite 200
Conshohocken PENNSYLVANIA US
Employees: 0
Phone: 16105407515
MEDICUS PHARMA LTD / MDCX FAQ
Can you describe the business of MEDICUS PHARMA LTD?
Medicus Pharma Ltd. is a biotech life sciences company, which focuses on accelerating the clinical development programs of novel and disruptive therapeutic assets. The company is headquartered in Conshohocken, Pennsylvania. The company went IPO on 2023-10-11. SkinJect Inc., a wholly owned subsidiary of the Company, is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver a chemotherapeutic agent to eradicate tumors cells. The company is conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in the United States and Europe. The company has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in the UAE. Its subsidiary, Antev Limited, is a late clinical stage biotech company, developing Teverelix, a GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse episodes due to enlarged prostate.
Can you provide the latest stock price for MEDICUS PHARMA LTD?
The current stock price of MDCX is 2.5075 USD. The price decreased by -7.13% in the last trading session.
Does MDCX stock pay dividends?
MDCX does not pay a dividend.
What is the ChartMill rating of MEDICUS PHARMA LTD stock?
MDCX has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the sector and industry classification for MEDICUS PHARMA LTD?
MEDICUS PHARMA LTD (MDCX) operates in the Health Care sector and the Biotechnology industry.
Can you provide the market cap for MEDICUS PHARMA LTD?
MEDICUS PHARMA LTD (MDCX) has a market capitalization of 50.70M USD. This makes MDCX a Micro Cap stock.
Can you provide the ownership details for MDCX stock?
You can find the ownership structure of MEDICUS PHARMA LTD (MDCX) on the Ownership tab.
MDCX Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to MDCX.
MDCX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to MDCX. MDCX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
MDCX Financial Highlights
Over the last trailing twelve months MDCX reported a non-GAAP Earnings per Share(EPS) of -1.87. The EPS increased by 24.18% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -195% | ||
| ROE | -319.45% | ||
| Debt/Equity | 0.07 |
MDCX Forecast & Estimates
9 analysts have analysed MDCX and the average price target is 20.06 USD. This implies a price increase of 700% is expected in the next year compared to the current price of 2.5075.